The contract research organisation (CRO) will provide the ultra-sensitive bioanalysis capacity at its facility in Worcester, Massachusetts as part of its “Discovery 2.0” suite of candidate assessment and characterisation services.
CEO Jim Jersey said that: “In launching the LC-MS-MS GLP bioanalytical services, we have challenged ourselves to be as innovative as we were in discovery, without compromising outstanding compliance and customer service."
The rapid expansion of Agilux service offering since its formation in 2007 is an indication of both the competitive nature of the bioanalysis sector and of growing drug industry demand for techniques that make the discovery process more efficient.